Clinical Accelerator is pleased to announce its collaboration with HVR Cardio on the development and clinical evaluation of CathHELIX, an innovative catheter-based device designed for mitral valve repair in patients with mitral regurgitation (MR). Clinical Accelerator is currently managing the clinical study aimed at assessing the safety and efficacy of CathHELIX as a novel transcatheter solution for MR.
Addressing the Unmet Needs of Mitral Valve Disease
Mitral regurgitation remains a challenging condition with limited therapeutic options, especially for patients who are not suitable candidates for surgery. The CathHELIX Transcatheter Mitral Repair Technology transforms the standard for surgical mitral valve repair into a transcatheter approach.
This device is designed to support a streamlined and safe procedural approach, making it accessible for routine use by interventional cardiologists.
The groundbreaking CathHELIX system reduces the mitral annulus and deploys a self-securing ring to the atrial and ventricular sides, reshaping the annulus and restoring native leaflet function.
As Clinical Accelerator continues to manage this study, its expertise in cardiovascular clinical trials positions it to deliver critical data, hopefully contributing to the advancement in the treatment of MR.
About Clinical Accelerator
Clinical Accelerator is an academically linked, full-service clinical trial management organization operating in Central and Eastern Europe and Central Asia. The company specializes in implementing successful and efficient early-stage First-In-Human (FIH) and Early Feasibility Studies (EFS) with a focus on rapid patient enrollment and high-quality data collection within compact timelines. Clinical Accelerator is dedicated to supporting the advancement of innovative medical treatments through rigorous and well-executed clinical trials.